BMRN Annual Operating Expenses
$1.75 B
+$179.87 M+11.48%
31 December 2023
Summary:
As of January 22, 2025, BMRN annual total operating expenses is $1.75 billion, with the most recent change of +$179.87 million (+11.48%) on December 31, 2023. During the last 3 years, it has risen by +$318.26 million (+22.29%). BMRN annual operating expenses is now at all-time high.BMRN Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Quarterly Operating Expenses
$443.39 M
-$17.73 M-3.84%
30 September 2024
Summary:
As of January 22, 2025, BMRN quarterly total operating expenses is $443.39 million, with the most recent change of -$17.73 million (-3.84%) on September 30, 2024. Over the past year, it has dropped by -$53.06 million (-10.69%). BMRN quarterly operating expenses is now -10.69% below its all-time high of $496.45 million, reached on December 31, 2023.BMRN Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BMRN Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +11.5% | -10.7% |
| 3 y3 years | +22.3% | +11.3% |
| 5 y5 years | +31.2% | +11.3% |
BMRN Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +20.4% | -10.7% | +19.6% |
| 5 y | 5-year | at high | +22.3% | -10.7% | +31.0% |
| alltime | all time | at high | >+9999.0% | -10.7% | >+9999.0% |
BioMarin Pharmaceutical Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $443.39 M(-3.8%) |
| June 2024 | - | $461.12 M(+3.6%) |
| Mar 2024 | - | $445.19 M(-10.3%) |
| Dec 2023 | $1.75 B(+11.5%) | $496.45 M(+15.2%) |
| Sept 2023 | - | $431.01 M(+8.0%) |
| June 2023 | - | $399.09 M(+0.1%) |
| Mar 2023 | - | $398.54 M(-8.2%) |
| Dec 2022 | $1.57 B(+8.0%) | $434.15 M(+11.2%) |
| Sept 2022 | - | $390.53 M(+5.4%) |
| June 2022 | - | $370.62 M(-0.1%) |
| Mar 2022 | - | $371.07 M(-5.9%) |
| Dec 2021 | $1.45 B(+1.5%) | $394.29 M(+10.6%) |
| Sept 2021 | - | $356.57 M(-1.2%) |
| June 2021 | - | $360.81 M(+6.6%) |
| Mar 2021 | - | $338.43 M(-8.0%) |
| Dec 2020 | $1.43 B(-1.5%) | $367.77 M(+7.5%) |
| Sept 2020 | - | $342.05 M(-8.2%) |
| June 2020 | - | $372.45 M(+7.9%) |
| Mar 2020 | - | $345.26 M(-3.3%) |
| Dec 2019 | $1.45 B(+8.9%) | $357.07 M(-0.9%) |
| Sept 2019 | - | $360.14 M(-1.8%) |
| June 2019 | - | $366.63 M(+0.3%) |
| Mar 2019 | - | $365.51 M(+11.5%) |
| Dec 2018 | $1.33 B(+9.9%) | $327.90 M(-0.2%) |
| Sept 2018 | - | $328.55 M(-3.1%) |
| June 2018 | - | $339.09 M(+1.1%) |
| Mar 2018 | - | $335.49 M(-3.9%) |
| Dec 2017 | $1.21 B(+9.0%) | $349.26 M(+21.1%) |
| Sept 2017 | - | $288.39 M(-3.9%) |
| June 2017 | - | $299.95 M(+9.5%) |
| Mar 2017 | - | $273.95 M(-15.9%) |
| Dec 2016 | $1.11 B(+9.0%) | $325.56 M(+12.6%) |
| Sept 2016 | - | $289.24 M(+30.2%) |
| June 2016 | - | $222.20 M(-19.1%) |
| Mar 2016 | - | $274.54 M(+10.1%) |
| Dec 2015 | $1.02 B(+29.5%) | $249.37 M(-2.5%) |
| Sept 2015 | - | $255.87 M(-7.4%) |
| June 2015 | - | $276.36 M(+16.2%) |
| Mar 2015 | - | $237.78 M(-5.1%) |
| Dec 2014 | $787.41 M(+28.0%) | $250.50 M(+23.4%) |
| Sept 2014 | - | $202.93 M(+13.1%) |
| June 2014 | - | $179.46 M(+15.6%) |
| Mar 2014 | - | $155.19 M(-14.2%) |
| Dec 2013 | $615.16 M(+18.5%) | $180.97 M(+13.4%) |
| Sept 2013 | - | $159.54 M(+18.8%) |
| June 2013 | - | $134.29 M(-4.3%) |
| Mar 2013 | - | $140.35 M(-7.9%) |
| Dec 2012 | $519.11 M(+32.7%) | $152.31 M(+33.6%) |
| Sept 2012 | - | $113.99 M(-13.2%) |
| June 2012 | - | $131.40 M(+8.2%) |
| Mar 2012 | - | $121.41 M(+12.7%) |
| Dec 2011 | $391.23 M | $107.76 M(+1.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $106.50 M(+13.4%) |
| June 2011 | - | $93.92 M(+9.1%) |
| Mar 2011 | - | $86.05 M(-5.1%) |
| Dec 2010 | $305.44 M(+26.0%) | $90.70 M(+16.7%) |
| Sept 2010 | - | $77.71 M(+6.6%) |
| June 2010 | - | $72.93 M(+12.6%) |
| Mar 2010 | - | $64.75 M(+1.2%) |
| Dec 2009 | $242.32 M(+18.7%) | $63.97 M(+14.8%) |
| Sept 2009 | - | $55.70 M(-5.0%) |
| June 2009 | - | $58.63 M(-8.4%) |
| Mar 2009 | - | $64.02 M(+15.2%) |
| Dec 2008 | $204.23 M(+27.2%) | $55.55 M(-1.2%) |
| Sept 2008 | - | $56.23 M(+12.3%) |
| June 2008 | - | $50.05 M(+18.1%) |
| Mar 2008 | - | $42.39 M(-14.5%) |
| Dec 2007 | $160.51 M(+60.3%) | $49.57 M(+31.0%) |
| Sept 2007 | - | $37.85 M(-0.2%) |
| June 2007 | - | $37.93 M(+6.8%) |
| Mar 2007 | - | $35.51 M(+18.5%) |
| Dec 2006 | $100.14 M(+14.8%) | $29.97 M(+13.4%) |
| Sept 2006 | - | $26.43 M(+10.1%) |
| June 2006 | - | $24.00 M(+21.5%) |
| Mar 2006 | - | $19.75 M(-5.8%) |
| Dec 2005 | $87.25 M(-46.3%) | $20.97 M(+1.9%) |
| Sept 2005 | - | $20.59 M(-6.1%) |
| June 2005 | - | $21.92 M(-7.8%) |
| Mar 2005 | - | $23.77 M(-74.8%) |
| Dec 2004 | $162.60 M(+85.0%) | $94.15 M(+251.7%) |
| Sept 2004 | - | $26.77 M(+19.8%) |
| June 2004 | - | $22.35 M(+15.6%) |
| Mar 2004 | - | $19.34 M(-23.0%) |
| Dec 2003 | $87.90 M(+30.0%) | $25.11 M(+21.5%) |
| Sept 2003 | - | $20.67 M(-4.2%) |
| June 2003 | - | $21.58 M(+5.0%) |
| Mar 2003 | - | $20.54 M(+32.8%) |
| Dec 2002 | $67.62 M(+42.0%) | $15.47 M(-16.9%) |
| Sept 2002 | - | $18.61 M(+13.5%) |
| June 2002 | - | $16.40 M(-4.4%) |
| Mar 2002 | - | $17.14 M(+106.9%) |
| Dec 2001 | $47.63 M(+4.9%) | $8.29 M(-36.9%) |
| Sept 2001 | - | $13.14 M(+0.7%) |
| June 2001 | - | $13.04 M(+17.2%) |
| Mar 2001 | - | $11.13 M(+32.1%) |
| Dec 2000 | $45.39 M(+46.0%) | $8.43 M(-34.0%) |
| Sept 2000 | - | $12.77 M(+8.2%) |
| June 2000 | - | $11.80 M(-4.8%) |
| Mar 2000 | - | $12.39 M(+202.4%) |
| Dec 1999 | $31.10 M(+110.1%) | $4.10 M(-65.0%) |
| Sept 1999 | - | $11.70 M(+33.0%) |
| June 1999 | - | $8.80 M(+33.9%) |
| Mar 1999 | - | $6.57 M |
| Dec 1998 | $14.80 M | - |
FAQ
- What is BioMarin Pharmaceutical annual total operating expenses?
- What is the all time high annual operating expenses for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual operating expenses year-on-year change?
- What is BioMarin Pharmaceutical quarterly total operating expenses?
- What is the all time high quarterly operating expenses for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly operating expenses year-on-year change?
What is BioMarin Pharmaceutical annual total operating expenses?
The current annual operating expenses of BMRN is $1.75 B
What is the all time high annual operating expenses for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual total operating expenses is $1.75 B
What is BioMarin Pharmaceutical annual operating expenses year-on-year change?
Over the past year, BMRN annual total operating expenses has changed by +$179.87 M (+11.48%)
What is BioMarin Pharmaceutical quarterly total operating expenses?
The current quarterly operating expenses of BMRN is $443.39 M
What is the all time high quarterly operating expenses for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly total operating expenses is $496.45 M
What is BioMarin Pharmaceutical quarterly operating expenses year-on-year change?
Over the past year, BMRN quarterly total operating expenses has changed by -$53.06 M (-10.69%)